Could a common diabetes drug save sight in glaucoma patients?
NCT ID NCT05426044
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether metformin, a drug used for diabetes, can protect the optic nerve and slow vision loss in people with glaucoma. 125 participants with worsening glaucoma will take either metformin or a placebo for 24 months. The goal is to see if metformin can slow the thinning of the nerve layer in the eye and preserve vision.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metformin
What this could lead to
If successful, this could show that metformin, a common diabetes drug, can protect the optic nerve and slow vision loss in glaucoma patients.
What could go wrong
This is a phase 2 trial with only 125 people, so results may not apply to everyone. It's also possible that metformin won't slow vision loss more than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
HKU Eye Centre
RECRUITINGWong Chuk Hang, Hong Kong
Contact Phone: •••-•••-••••